| Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study B Waschki, A Kirsten, O Holz, KC Müller, T Meyer, H Watz, H Magnussen Chest 140 (2), 331-342, 2011 | 1257 | 2011 |
| Withdrawal of inhaled glucocorticoids and exacerbations of COPD H Magnussen, B Disse, R Rodriguez-Roisin, A Kirsten, H Watz, K Tetzlaff, ... New England Journal of Medicine 371 (14), 1285-1294, 2014 | 789 | 2014 |
| Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial H Watz, K Tetzlaff, EFM Wouters, A Kirsten, H Magnussen, ... The lancet Respiratory medicine 4 (5), 390-398, 2016 | 504 | 2016 |
| Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation H Watz, B Waschki, T Meyer, G Kretschmar, A Kirsten, M Claussen, ... Chest 138 (1), 32-38, 2010 | 378 | 2010 |
| The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity H Watz, B Waschki, A Kirsten, KC Müller, G Kretschmar, T Meyer, O Holz, ... Chest 136 (4), 1039-1046, 2009 | 375 | 2009 |
| Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme N Krug, JM Hohlfeld, AM Kirsten, O Kornmann, KM Beeh, D Kappeler, ... New England Journal of Medicine 372 (21), 1987-1995, 2015 | 326 | 2015 |
| Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease B Waschki, AM Kirsten, O Holz, KC Mueller, M Schaper, AL Sack, T Meyer, ... American journal of respiratory and critical care medicine 192 (3), 295-306, 2015 | 299 | 2015 |
| The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease KM Beeh, J Westerman, AM Kirsten, J Hébert, L Grönke, A Hamilton, ... Pulmonary pharmacology & therapeutics 32, 53-59, 2015 | 155 | 2015 |
| Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week … J Beier, AM Kirsten, R Mróz, R Segarra, F Chuecos, C Caracta, EG Gil COPD: Journal of Chronic Obstructive Pulmonary Disease 10 (4), 511-522, 2013 | 149 | 2013 |
| Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD R Fuhr, H Magnussen, K Sarem, AR Llovera, AM Kirsten, M Falqués, ... Chest 141 (3), 745-752, 2012 | 137 | 2012 |
| Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study C Vogelmeier, PL Paggiaro, J Dorca, P Sliwinski, M Mallet, AM Kirsten, ... European Respiratory Journal 48 (4), 1030-1039, 2016 | 108 | 2016 |
| Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension L Richeldi, M Kreuter, M Selman, B Crestani, AM Kirsten, WA Wuyts, Z Xu, ... Thorax 73 (6), 581-583, 2018 | 85 | 2018 |
| Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD DE O'Donnell, R Casaburi, P Frith, A Kirsten, D De Sousa, A Hamilton, ... European Respiratory Journal 49 (4), 2017 | 85 | 2017 |
| Clinical correlates of reduced physical activity in idiopathic pulmonary fibrosis T Bahmer, AM Kirsten, B Waschki, KF Rabe, H Magnussen, D Kirsten, ... Respiration 91 (6), 497-502, 2016 | 84 | 2016 |
| Effect of fissure integrity on lung volume reduction using a polymer sealant* in advanced emphysema H Magnussen, MR Kramer, AM Kirsten, C Marquette, A Valipour, ... Thorax 67 (4), 302-308, 2012 | 80 | 2012 |
| The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD AM Kirsten, K Förster, E Radeczky, A Linnhoff, B Balint, H Watz, H Wray, ... Pulmonary pharmacology & therapeutics 31, 36-41, 2015 | 79 | 2015 |
| Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study TM Maher, S Stowasser, Y Nishioka, ES White, V Cottin, I Noth, M Selman, ... The Lancet respiratory medicine 7 (9), 771-779, 2019 | 77 | 2019 |
| Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis T Bahmer, AM Kirsten, B Waschki, KF Rabe, H Magnussen, D Kirsten, ... BMC pulmonary medicine 17, 1-8, 2017 | 77 | 2017 |
| Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD A Cahn, JN Hamblin, M Begg, R Wilson, L Dunsire, S Sriskantharajah, ... Pulmonary pharmacology & therapeutics 46, 69-77, 2017 | 75 | 2017 |
| Physical activity patterns and clusters in 1001 patients with COPD R Mesquita, G Spina, F Pitta, D Donaire-Gonzalez, BM Deering, MS Patel, ... Chronic respiratory disease 14 (3), 256-269, 2017 | 75 | 2017 |
Klaus F. RabeLungenClinic GrosshansdorfBestätigte E-Mail-Adresse bei lungenclinic.de
